Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -96.53% | -91.75% | -97.94% | -65.23% | -10.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.53% | -91.75% | -97.94% | -65.23% | -10.63% |
| Cost of Revenue | -3.44% | 22.73% | 18.24% | 12.12% | 18.08% |
| Gross Profit | -875.50% | -214.43% | -157.34% | -137.74% | -70.55% |
| SG&A Expenses | -5.16% | 3.34% | 18.25% | 9.31% | 13.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.83% | 18.04% | 18.24% | 11.42% | 17.11% |
| Operating Income | -587.03% | -117.25% | -187.69% | -203.21% | -219.61% |
| Income Before Tax | -5,187.14% | -173.60% | -174.28% | -168.50% | -108.04% |
| Income Tax Expenses | 104.92% | 135.16% | -93.55% | -- | -109.98% |
| Earnings from Continuing Operations | -3,562.78% | -214.52% | -178.32% | -173.84% | 111.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,562.78% | -214.52% | -178.32% | -173.84% | 111.85% |
| EBIT | -587.03% | -117.25% | -187.69% | -203.21% | -219.61% |
| EBITDA | -708.66% | -121.13% | -184.32% | -194.54% | -186.42% |
| EPS Basic | -3,498.56% | -208.16% | -164.76% | -160.22% | 109.69% |
| Normalized Basic EPS | -4,841.59% | -168.06% | -161.42% | -155.86% | -106.56% |
| EPS Diluted | -4,692.20% | -204.11% | -167.27% | -162.12% | 107.17% |
| Normalized Diluted EPS | -5,118.69% | -168.06% | -163.80% | -158.02% | -106.21% |
| Average Basic Shares Outstanding | 1.86% | 2.05% | 20.94% | 22.62% | 22.40% |
| Average Diluted Shares Outstanding | -3.36% | 2.05% | 16.42% | 18.06% | 29.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |